What is the Diamox (acetazolamide) challenge in normal-pressure hydrocephalus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is the Diamox Challenge in NPH?

The Diamox (acetazolamide) challenge test is a diagnostic procedure used to predict which normal pressure hydrocephalus (NPH) patients will benefit from CSF shunting by measuring intracranial pressure (ICP) response to intravenous acetazolamide administration—patients whose ICP increases by more than 10 mmHg are considered good shunt candidates.

Mechanism and Procedure

The test involves administering 500-1000 mg of acetazolamide intravenously while monitoring ICP changes, typically through lumbar subarachnoid pressure measurement 1, 2. Acetazolamide, as a carbonic anhydrase inhibitor, reduces CSF production at the choroid plexus 3, 4, and the ICP response reveals information about CSF circulation dynamics.

Interpretation for Shunt Selection

Positive Test (Good Shunt Candidates)

  • ICP increase >10 mmHg (or >50% from baseline) after acetazolamide administration 1, 2
  • This response indicates poor CSF circulation and impaired compensatory mechanisms
  • These patients typically show definite clinical improvement after VP shunt placement 1, 2
  • Post-operatively, the ICP response to acetazolamide decreases to <10 mmHg in successful cases 1

Negative Test (Poor Shunt Candidates)

  • ICP increase <10 mmHg (or <25% from baseline) 1, 2
  • Suggests preserved autoregulation but likely irreversible brain damage
  • These patients generally do not improve with shunting 1

Cerebrovascular Reactivity Component

Beyond ICP monitoring, some centers measure cerebral blood flow (CBF) response to acetazolamide using SPECT or xenon-enhanced CT 5, 6, 7:

  • Impaired cerebrovascular reactivity (CVR <20% increase in CBF) predicts shunt responsiveness with 100% sensitivity 7
  • Responders show impaired CVR specifically in periventricular white matter with preserved cortical response 5
  • Preoperative CBF >20 ml/100g/min combined with impaired white matter CVR indicates likely benefit 5
  • Post-shunt, successful patients show restoration of both CBF and CVR 6

Clinical Context and Caveats

Important limitation: Acetazolamide is not an effective treatment for NPH itself—only a diagnostic test 8. The drug reduces ICP temporarily but does not provide sustained clinical benefit for NPH symptoms.

The test works because it stresses the CSF circulation system: in patients with compromised CSF dynamics (true NPH), the system cannot compensate for acetazolamide-induced changes, leading to exaggerated ICP responses. In contrast, patients with brain atrophy or other causes of ventriculomegaly maintain normal compensatory mechanisms and show minimal ICP changes.

Correlation with other findings: The acetazolamide test response correlates with B-wave appearance on continuous pressure monitoring 2, and patients with the radiographic pattern of DESH (disproportionately enlarged subarachnoid-space hydrocephalus) are more likely to have positive tests 9.

The test is simple, safe, and cost-effective compared to prolonged ICP monitoring or invasive tap tests 1, making it a valuable tool in the diagnostic algorithm for selecting appropriate shunt candidates in NPH.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.